Overall, these platforms offer a potentially powerful framework for precision cancer immunotherapy, however, successful clinical translation will require stronger evidence regarding safety, controllability, manufacturing consistency, and therapeutic efficacy.
Jia Lin, Ming An, Yuxin Dai et al.· Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.